Myocet (Non-pegylated liposomal doxorubicin (NPLD))
LAPADO-Study
Phase 2 small_molecule completed
Quick answer
Myocet (Non-pegylated liposomal doxorubicin (NPLD)) for Breast Cancer is a Phase 2 program (small_molecule) at Sana Biotechnology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sana Biotechnology
- Indication
- Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed